

Eff. Date: 4 March 2020 Version: 2.0 IFU: Podoplanin ILM4174

Podoplanin clone D2-40

Instructions for Use

Specification:

Podoplanin is a transmembrane mucoprotein (38 kDa) recognized by the D2-40 monoclonal antibody. Podoplanin is selectively expressed in lymphatic endothelium as well as lymphangiomas, Kaposi sarcomas and in a subset of angiosarcomas with probable lymphatic differentiation. Podoplanin has also been shown to be expressed in epithelioid mesotheliomas hemangioblastomas and seminomas.

Availability:

Catalog No.	Contents	Volume
ILM4174-C01	Podoplanin	0,1 ml concentrate
ILM4174-C05	Podoplanin	0,5 ml concentrate
ILM4174-C1	Podoplanin	1,0 ml conentrate

Intended use: For Research Use Only

Reactivity: Human


Clone: D2-40

Species of origin: Mouse

Isotype: IgG1

Control Tissue: Lymphangioma, lymph node, tonsil

Staining: Cytoplasmic



Presentation: Anti-Podoplanin is a mouse monoclonal antibody from supernatant diluted in tris buffered saline, pH 7.3-7.7, with protein base, and preserved with sodium azide.

Application and suggested dilutions:

Pre-treatment: Heat induced epitope retrieval in 10 mM citrate buffer pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

- Immunohistochemical staining of cryostat tissue sections (dilution up to 1:20-1:100)
- Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section (dilution up to 1:20-1:100)

The optimal dilution for a specific application should be determined by the investigator.

Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended.

Storage & Stability: Store at 2-8 °C. Do not use after expiration date printed on the vial.

References:

- 1) Ordonez N. Adv Anat Pathol. 2006 Mar;13(2):83-8
- 2) Ordonez N. Hum Pathol. 2005 Apr;36(4):372-80
- 3) Niakosari F et al. Arch Dermatol. 2005 Apr;141(4):440-4
- 4) Galambos C, Nodit L. Pediatr Dev Pathol. 2005 Mar-Apr;8(2):191-9
- 5) Fukunaga M. Histopathology. 2005 Apr;46(4):396-402
- 6) Chu AY et al. Mod Pathol. 2005 Jan;18(1):105-10
- 7) Franke FE et al. J Cutan Pathol. 2004 May;31(5):362-7
- 8) Fogt F et al. Oncol Rep. 2004 Jan;11(1):47-50
- 9) Kahn HJ et al. Mod Pathol. 2002 Apr;15(4):434-40

WellMed BV, 't Holland 31, 6921 GX Duiven, The Netherlands

Ľ	+ 31 (0) 85 273 23 23
$\mathbf{\Sigma}$	info@wellmed nl